Loading
Kodiak Sciences Inc. Stock: price and insider trades · United States
1 insider bought €137.9M of shares over the last 90 days, the latest filed 30 Sept 2026.
Kodiak Sciences Inc.: what insiders have been doing
Every trade that managers of Kodiak Sciences Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 4 insiders published 97 filings.
On the market, 1 insider bought (83 purchases totalling €142.1M) while 1 insider sold (6 sales totalling €1.9M). Netting one side against the other leaves €140.2M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 senior executive. Biggest ticket of the year: €17.7M, bought by Baker Bros. Advisors LP and made public on 30 September 2026 (0.35% of market cap).
The clock since the last published purchase (30 September 2026) now reads 18 days. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 97 filings here. Since 2021, the database holds 94 purchases and 13 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -230.0 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
136
Thresholds
n/a
Buy Volume
€155M
94 ops. · all time
Sell Volume
€11M
13 ops. · all time
Who traded when
BuySaleBaker Bros. Advisors LP83 buys
John A. Borgeson6 sales
Since the insiders bought
- -22.2%Entry US$28.61 · Close at T+90 US$22.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kodiak Sciences Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$121.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$85.75
Analyst consensus
6 analystsStrong buy
US$103.00Target US$121.67(+42%)US$145.00
Income statement
EBITDA-US$203.6M
Net income-US$230M0.0% margin
Valuation
PER (forward)-25.0x
P/Book88.0x
Beta2.04
Balance sheet & cash
Market capUS$5.4B
Total debtUS$59.2M
Free Cash Flow-US$136.5M
Debt / Equity86%
Profitability & ownership
ROE-368.4%
ROA-60.4%
% insiders5.2%
% institutions105.6%
Last declaration on 30 September 2026
Declarations136 total
6,428 shares@ US$88.6460.0099% mcap0.3% of flowCommon StockSEC:0001193125-26-409127:10
Canonical exit: 27 Dec 2026 (T+90)
619 shares@ US$84.24210.0009% mcap0.0% of flowCommon StockSEC:0001193125-26-409127:16
Canonical exit: 28 Dec 2026 (T+90)
17 shares@ US$79.630.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-409118:2
Canonical exit: 27 Dec 2026 (T+90)
17,490 shares@ US$81.31390.025% mcap0.8% of flowCommon StockSEC:0001193125-26-409118:15
Canonical exit: 27 Dec 2026 (T+90)
1,699 shares@ US$82.68220.0024% mcap0.1% of flowCommon StockSEC:0001193125-26-409118:21
Canonical exit: 27 Dec 2026 (T+90)
2,322 shares@ US$85.96560.0035% mcap0.1% of flowCommon StockSEC:0001193125-26-409118:28
Canonical exit: 27 Dec 2026 (T+90)
14,344 shares@ US$61.21040.015% mcap0.5% of flowCommon StockSEC:0001193125-26-409116:1
Canonical exit: 27 Dec 2026 (T+90)
2,666 shares@ US$61.62520.0029% mcap0.1% of flowCommon StockSEC:0001193125-26-409116:2
Canonical exit: 27 Dec 2026 (T+90)
44,690 shares@ US$61.62520.048% mcap1.6% of flowCommon StockSEC:0001193125-26-409116:3
Canonical exit: 27 Dec 2026 (T+90)
321 shares@ US$67.09670.0004% mcap0.0% of flowCommon StockSEC:0001193125-26-409116:8
Canonical exit: 27 Dec 2026 (T+90)
16,641 shares@ US$72.38730.021% mcap0.7% of flowCommon StockSEC:0001193125-26-409116:16
Canonical exit: 27 Dec 2026 (T+90)
196,608 shares@ US$89.85550.31% mcap10.3% of flowCommon StockSEC:0001193125-26-409127:15
Canonical exit: 27 Dec 2026 (T+90)
186 shares@ US$86.72170.0003% mcap0.0% of flowCommon StockSEC:0001193125-26-409127:0
Canonical exit: 27 Dec 2026 (T+90)
3,114 shares@ US$86.72170.0047% mcap0.2% of flowCommon StockSEC:0001193125-26-409127:1
Canonical exit: 27 Dec 2026 (T+90)
957 shares@ US$86.81420.0014% mcap0.0% of flowCommon StockSEC:0001193125-26-409127:2
Canonical exit: 27 Dec 2026 (T+90)
16,036 shares@ US$86.81420.024% mcap0.8% of flowCommon StockSEC:0001193125-26-409127:3
Canonical exit: 27 Dec 2026 (T+90)
3,790 shares@ US$86.94210.0057% mcap0.2% of flowCommon StockSEC:0001193125-26-409127:4
Canonical exit: 27 Dec 2026 (T+90)
63,539 shares@ US$86.94210.096% mcap3.2% of flowCommon StockSEC:0001193125-26-409127:5
Canonical exit: 27 Dec 2026 (T+90)
4,485 shares@ US$87.50650.0068% mcap0.2% of flowCommon StockSEC:0001193125-26-409127:6
Canonical exit: 27 Dec 2026 (T+90)
75,176 shares@ US$87.50650.11% mcap3.8% of flowCommon StockSEC:0001193125-26-409127:7
Canonical exit: 27 Dec 2026 (T+90)
5,880 shares@ US$88.56710.0091% mcap0.3% of flowCommon StockSEC:0001193125-26-409127:8
Canonical exit: 27 Dec 2026 (T+90)
98,561 shares@ US$88.56710.15% mcap5.1% of flowCommon StockSEC:0001193125-26-409127:9
Canonical exit: 27 Dec 2026 (T+90)
107,772 shares@ US$88.6460.17% mcap5.6% of flowCommon StockSEC:0001193125-26-409127:11
Canonical exit: 27 Dec 2026 (T+90)
4,932 shares@ US$89.60360.0077% mcap0.3% of flowCommon StockSEC:0001193125-26-409127:12
Canonical exit: 27 Dec 2026 (T+90)
82,673 shares@ US$89.60360.13% mcap4.3% of flowCommon StockSEC:0001193125-26-409127:13
Canonical exit: 27 Dec 2026 (T+90)
25 of 136 declarations
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq in the United States. The company is focused on researching, developing, and, ultimately, commercializing transformative retinal therapies. Founded in 2009, Kodiak has positioned itself as a retina-focused, science-driven biotech operating in one of the most competitive yet medically important segments of ophthalmology. Its strategy is anchored in addressing major unmet needs in retinal disease, an area where better durability, improved efficacy, and more convenient dosing remain key differentiators versus existing standards of care.
Kodiak describes itself as a precommercial company, meaning it is still in the clinical-development stage and has not yet built a broad marketed product franchise. The core of its scientific platform is the ABC technology, which the company uses to design next-generation retinal medicines with the goal of combining strong biological activity with longer duration of effect. Kodiak’s most closely watched programs include KSI-501, KSI-101, and tarcocimab, each aimed at high-value retinal indications and designed to compete in disease areas with significant clinical unmet need. In practical terms, the company’s value proposition rests on whether these assets can deliver meaningful advantages in efficacy, durability, or treatment burden versus current therapies.
Read moreShow less
From a competitive standpoint, Kodiak operates in a field dominated by larger pharmaceutical companies and well-funded ophthalmology specialists. That makes clinical differentiation especially important. Success depends not only on scientific novelty, but also on clean safety data, reproducible efficacy, and the ability to translate platform science into commercially meaningful products. Kodiak’s pipeline-centric model also means that investor attention is heavily concentrated on clinical milestones, regulatory progress, and data readouts rather than near-term product sales.
Geographically, Kodiak is headquartered in the United States and is part of the U.S. public-market biotech ecosystem, with reporting and disclosure obligations under SEC rules. Recent company updates show an active capital-markets and development agenda, including equity financings in 2025 and early 2026, as well as recurring business updates tied to pipeline advancement. Kodiak has indicated that its three Phase 3 assets are on track for topline data in 2026, making that year potentially decisive for the company’s long-term trajectory. For investors, Kodiak Sciences remains a high-risk, high-upside specialty biotech story tied to retina innovation, clinical execution, and the ability to convert platform science into durable competitive advantage.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
